Market Exclusive

Analyst Downgrades – NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX) Stock Gets Downgraded By Cantor Fitzgerald from Overweight to Neutral

Analyst Ratings For NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX)

Today, NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX) stock was downgraded by Cantor Fitzgerald from Overweight to Neutral with a price target of $3.00.

Some recent analyst ratings include

Recent Insider Trading Activity For NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX)
NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX) has insider ownership of 4.10% and institutional ownership of 55.49%.

Recent Trading Activity for NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX)
Shares of NASDAQ:CLDX – Celldex Therapeutics closed the previous trading session at 0.88 up +0.12 15.24% with 0.800000011920929 shares trading hands.

Exit mobile version